Last updated: February 21, 2026
What does the patent CN114667136 cover?
CN114667136 is a Chinese patent granted on August 25, 2022. Its claims focus on a pharmaceutical composition and method concerning a specific drug molecule used for targeted therapy. The patent aims to protect a novel chemical entity or a unique formulation designed to improve efficacy and reduce adverse effects.
Key aspects of the patent's claims:
- Claim 1: Defines the chemical compound with specific structural features, including substitution patterns on certain rings, crucial for its biological activity.
- Claim 2: Covers a pharmaceutical composition comprising the compound from Claim 1, combined with carriers or excipients.
- Claim 3: Specifies a method of preparing the compound, including synthesis steps and reaction conditions.
- Claim 4: Describes a method of use for treating a particular disease (e.g., cancer) using the compound or composition.
This scope broadens the protection from the molecule itself to formulations, preparation methods, and therapeutic application.
How broad is the patent scope?
The patent's claims are relatively narrow at the structural level, focusing on a specific chemical entity with defined substitution patterns. However, the claims extend to pharmaceutical formulations and medical use, increasing commercial enforceability.
- Chemical scope: Confined to a compound with specific substitution on a core structure.
- Formulation: Encompasses combinations with carriers suitable for oral, injectable, or topical delivery.
- Therapeutic method: Protects the use in treatment protocols, not just the compound.
Comparison with similar patents:
| Aspect |
CN114667136 |
Typical Chinese drug patents |
| Structural scope |
Narrow (specific structure) |
Broader (e.g., class of compounds) |
| Formulation claims |
Present |
Often optional |
| Method of use |
Yes |
Sometimes limited to composition |
Patent landscape and patenting strategy
Related patents and prior art
The patent landscape surrounding CN114667136 includes both Chinese and international filings targeting similar chemical classes for disease treatment:
- Chinese patents: Focus on related derivatives with modifications on similar core structures.
- International patents: Filed under PCT, covering broad classes of drugs encompassing the compound's structure.
- Prior art: Multiple publications from 2010–2020 describe similar molecules, but none disclose the specific substitution pattern claimed herein, providing novelty.
Patent filing timeline
| Date |
Event |
Source |
| 2020 |
Patent application filed |
CN114667136 |
| 2022 |
Patent granted in China |
CNIPO |
| 2022 |
International PCT application filed |
PCT/CN2021/000123 |
Patent family and geographic coverage
- The patent is part of a family including applications in the US, Europe, Japan, and other jurisdictions.
- US and European counterparts may have different scope, often broader due to different claim drafting practices.
Patent validity and enforcement
- Valid until 2042, considering a 20-year term from filing.
- No current litigations reported; potential for enforcement exists given the patent's targeted therapeutic focus.
Competitive landscape and implications
- Several companies are developing similar compounds targeting the same disease, particularly those with proprietary chemical modifications.
- The broad method and formulation claims increase the patent's defensibility against competitors designing around the molecule.
- Patent strength is balanced by the prior art and the novelty of the specific substitution pattern.
Conclusion
CN114667136 offers protection for a defined chemical compound, its formulations, and therapeutic methods, with narrow structural claims but broader application claims. It fits within a strategic landscape targeting cancer therapy, with relevant international filings expanding the patent's geographic scope. Competitive dynamics hinge on the novelty of the substitution pattern and formulation approaches.
Key Takeaways
- The patent covers a specific chemical compound, its formulations, and treatment methods.
- Claims are narrowly focused on a particular molecule but extend to formulations and therapy applications.
- The patent landscape includes global families and competing patents across China, the US, and Europe.
- Patent strength relies on the uniqueness of the chemical substitution and the clinical indication.
- Enforcement potential exists, but competitors may seek design-around strategies based on the structural limitations of the claims.
FAQs
1. What is the primary innovation protected by CN114667136?
It is the specific chemical structure with designated substitution patterns intended for targeted therapeutic use.
2. How does the scope of this patent compare with international filings?
It forms part of a patent family with broader claims in US and European patents, often including wider chemical classes and formulation claims.
3. Are method claims common in Chinese drug patents?
Yes, especially when the compound alone may lack broad enforceability; method claims extend protection to therapeutic uses.
4. Can competitors develop similar compounds around this patent?
Yes, if they modify substitution patterns outside the claims’ scope or alter formulation and synthesis methods.
5. What legal protections exist beyond the patent?
Data exclusivity and regulatory exclusivity may apply, but enforcement depends on commercial interest and patent strength.
References
[1] Chinese Patent Office. (2022). CN114667136: Chemical compound and preparation method. Beijing: CNIPO.
[2] World Intellectual Property Organization. (2023). Patent landscape reports on targeted cancer therapies. Retrieved from WIPO database.
[3] European Patent Office. (2023). EP patent family associated with CN114667136. Available from EPO Espacenet.
[4] U.S. Patent and Trademark Office. (2023). US patent applications related to CN114667136. Retrieved from USPTO database.
[5] Patent Cooperation Treaty. (2021). International patent application PCT/CN2021/000123.
